PMID- 35432564
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220507
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - Zhenzhu Xiaoji Decoction Induces Autophagy and Apoptosis Cell Death in Liver 
      Cancer Cells through AKT/mTOR and JAK2/STAT3 Signaling Pathway.
PG  - 4445293
LID - 10.1155/2022/4445293 [doi]
LID - 4445293
AB  - BACKGROUND: Liver cancer is one of the most common digestive tumors. The 
      prescription Zhenzhu Xiaoji decoction (ZZXJD) has a certain effect on the growth 
      and survival of primary liver cancer. Object: This article aimed to explore the 
      effect and molecular mechanism of ZZXJD on liver cancer SMMC-7721 cells. METHOD: 
      The research groups were divided into the model group, ZZXJD group, and cisplatin 
      group. SMMC-7721 cells were treated with different concentrations of 
      ZZXJD-medicated serum for 24 h and 48 h. The cell viability was measured with 
      CCK8 assay, and cell morphology was observed by fluorescence microscope and 
      transmission electron microscope (TEM). Western blot, RT-PCR, and gene chip were 
      used to determine the protein expression level and gene expression level of cells 
      and tumor tissues. RESULTS: ZZXJD inhibited the proliferation activity of 
      SMMC-7721 cells in a concentration- and time-dependent manner. The morphological 
      changes of the cell showed apoptosis and autophagy. The gene expression of 
      protein kinase B (AKT), mammalian target of rapamycin (mTOR), Janus kinase 2 
      (JAK2), and signal transducer and activator of transcription 3(STAT3) were 
      downregulated compared with the model group(p < 0.05). The nude mice experiments 
      confirmed that ZZXJD inhibited the growth of tumors in tumor-bearing mice, and 
      the effect increased with the increase of concentration. CONCLUSION: ZZXJD 
      induced autophagy and apoptosis of liver cancer cells via inhibiting AKT/mTOR 
      signaling pathway and JAK2/STAT3 signaling pathway, thereby affecting the growth 
      and survival of liver cancer cells.
CI  - Copyright (c) 2022 Yang Sun et al.
FAU - Sun, Yang
AU  - Sun Y
AUID- ORCID: 0000-0003-4312-6327
AD  - Department of Biology, College of Basic Medicine, Heilongjiang University of 
      Chinese Medicine, Harbin 150040, Heilongjiang, China.
FAU - Sun, Yue
AU  - Sun Y
AD  - Department of Biology, College of Basic Medicine, Heilongjiang University of 
      Chinese Medicine, Harbin 150040, Heilongjiang, China.
FAU - Li, Songzhe
AU  - Li S
AD  - Department of Biology, College of Basic Medicine, Heilongjiang University of 
      Chinese Medicine, Harbin 150040, Heilongjiang, China.
FAU - Tao, Xuelian
AU  - Tao X
AD  - Department of Biology, College of Basic Medicine, Heilongjiang University of 
      Chinese Medicine, Harbin 150040, Heilongjiang, China.
FAU - Cai, Lingyun
AU  - Cai L
AD  - Department of Biology, College of Basic Medicine, Heilongjiang University of 
      Chinese Medicine, Harbin 150040, Heilongjiang, China.
LA  - eng
PT  - Journal Article
DEP - 20220406
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC9007645
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/19 06:00
MHDA- 2022/04/19 06:01
PMCR- 2022/04/06
CRDT- 2022/04/18 06:34
PHST- 2021/10/28 00:00 [received]
PHST- 2022/01/20 00:00 [revised]
PHST- 2022/03/08 00:00 [accepted]
PHST- 2022/04/18 06:34 [entrez]
PHST- 2022/04/19 06:00 [pubmed]
PHST- 2022/04/19 06:01 [medline]
PHST- 2022/04/06 00:00 [pmc-release]
AID - 10.1155/2022/4445293 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Apr 6;2022:4445293. doi: 
      10.1155/2022/4445293. eCollection 2022.